Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2022 07:30 ET | Source: Morphic Therapeutic

Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
May 17, 2022 08:00 ET | Source: Morphic Therapeutic

Morphic Announces Participation in 2022 RBC Capital Markets Global Healthcare Conference

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
May 12, 2022 08:00 ET | Source: Morphic Therapeutic

Morphic Names Bruce Rogers as President of Morphic Therapeutic and Blaise Lippa as Chief Scientific Officer

WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
May 04, 2022 08:00 ET | Source: Morphic Therapeutic

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022

Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Described new understanding of α4β7-expressing immune cells and MORF-057 dose response in oral presentation at ECCO...
April 06, 2022 08:00 ET | Source: Morphic Therapeutic

Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development

Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leaderAaron Pelta promoted to Senior Vice President, Business and Corporate Development;...
March 30, 2022 08:00 ET | Source: Morphic Therapeutic

Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
March 25, 2022 08:00 ET | Source: Morphic Therapeutic

Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative Colitis

MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase 2b EMERALD-2 clinical trial of MORF-057 expected to begin mid-year 2022 WALTHAM,...
March 04, 2022 09:05 ET | Source: Morphic Therapeutic

Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference

WALTHAM, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
February 24, 2022 07:30 ET | Source: Morphic Therapeutic

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2021

Presented positive Phase 1 data for MORF-057 Phase 2a trial in patients with ulcerative colitis scheduled to begin 1Q22; Phase 2b to commence mid-year Presented preclinical data from αvβ8 program at...
February 22, 2022 08:00 ET | Source: Morphic Therapeutic

Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022

New preclinical data expand understanding of α4β7-expressing immune cells and MORF-057 dose response Data support ongoing clinical development program in IBD WALTHAM, Mass., Feb. 22, 2022 ...